Smartleaf Asset Management LLC Has $70,000 Position in NeoGenomics, Inc. (NASDAQ:NEO)

Smartleaf Asset Management LLC grew its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 203.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,156 shares of the medical research company’s stock after buying an additional 2,787 shares during the quarter. Smartleaf Asset Management LLC’s holdings in NeoGenomics were worth $70,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Proficio Capital Partners LLC acquired a new position in shares of NeoGenomics in the 4th quarter worth approximately $372,000. Bank of New York Mellon Corp grew its position in NeoGenomics by 1.8% in the fourth quarter. Bank of New York Mellon Corp now owns 849,752 shares of the medical research company’s stock valued at $14,004,000 after acquiring an additional 15,269 shares during the period. Handelsbanken Fonder AB raised its stake in NeoGenomics by 12.3% during the fourth quarter. Handelsbanken Fonder AB now owns 28,300 shares of the medical research company’s stock worth $466,000 after acquiring an additional 3,100 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of NeoGenomics by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 622,849 shares of the medical research company’s stock valued at $10,265,000 after acquiring an additional 18,455 shares during the period. Finally, Strategic Financial Concepts LLC acquired a new stake in shares of NeoGenomics in the 4th quarter valued at $220,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Trading Down 4.2 %

Shares of NEO opened at $10.10 on Monday. The stock’s fifty day simple moving average is $13.79 and its 200-day simple moving average is $15.01. The firm has a market capitalization of $1.30 billion, a PE ratio of -16.29 and a beta of 1.28. NeoGenomics, Inc. has a 12-month low of $8.98 and a 12-month high of $19.11. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The business had revenue of $172.00 million during the quarter, compared to the consensus estimate of $173.40 million. As a group, research analysts predict that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

Analyst Ratings Changes

NEO has been the subject of a number of recent analyst reports. Piper Sandler dropped their target price on shares of NeoGenomics from $21.00 to $18.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Jefferies Financial Group began coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They set a “buy” rating and a $22.00 price objective for the company. Needham & Company LLC reduced their target price on NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, February 19th. Benchmark cut NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Bank of America cut their price objective on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.60.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.